logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Nateglinide CAS 105816-04-4 API Active Pharmaceutical Ingredient

Nateglinide CAS 105816-04-4 API Active Pharmaceutical Ingredient

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 105816-04-4

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,Western Union,MoneyGram,T/T

Supply Ability: G,KG,TON

Get Best Price
Highlight:

Nateglinide

,

Nateglinide CAS 105816-04-4

CAS NO::
105816-04-4
Appearance::
White Crystalline Powder
Molecular Formula::
C19H27NO3
Molecular Weight::
317.42300
EINECS NO::
642-283-9
MDL NO::
MFCD00875706
CAS NO::
105816-04-4
Appearance::
White Crystalline Powder
Molecular Formula::
C19H27NO3
Molecular Weight::
317.42300
EINECS NO::
642-283-9
MDL NO::
MFCD00875706
Nateglinide CAS 105816-04-4 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Nateglinide CAS NO: 105816-04-4                       


Synonyms:

N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine;

Glinate;

Starsis;


Chemical & Physical Properties:

Appearance: White crystalline powder

Assay :≥99.0%

Density: 1.104 g/cm3

Boiling Point: 527.6℃ at 760 mmHg

Melting Point: 137-141℃

Flash Point: 272.9℃

Refractive Index: 1.536

Storage Condition: Room temp

Vapor Pressure: 0mmHg at 25℃


Safety Information:

RTECS: SQ7318950

Safety Statements: S24/25; S36

HS Code: 2924299090

Risk Statement: R22

Hazard Code: Xn


Nateglinide is a N-acylated D-phenylalanine marketed in Japan as novel orally active insulinotropic agent for the treatment of type-2 diabetes mellitus. It belongs to the class of nonsulfonylureas and shows some structural similarity to repaglinide, the only other representative in this family. In single pancreatic beta-cells isolated from rats, Nateglinide was found to specifically block the ATP-sensitive K+ channel resulting in an increase in intracellular calcium concentration. This primary action would underlie the mechanism by which Nateglinide markedly stimulates or potentiates, depending on glucose concentrations, insulin secretion from pancreatic beta-cells. Clinical studies demonstrated a good safety profile with a low potential for hypoglycemia. The pharmacokinetic profile was consistent with the changes of the blood glucose and plasma insulin level. Interestingly, Nateglinide exerts a rapid onset and short duration of action due to a rapid absorption and clearance. Unlike other similar agents, Nateglinide suppresses postprandial glucose elevations.Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.